65,437 trials
Hepatitis C Virus Infection · Human Immunodeficiency Virus Infection · Chronic Hepatitis C
Primary: Percentage of Participants in GT1 Analysis Group 1 in Part 2 Achieving Sustained Virologic Response 12 Weeks Post-Treatment (SVR12) — 97.0 percentage of participants
Influenza
Primary: Number of Seroconverted (SCR) Subjects for Hemagglutination Inhibition (HI) Antibodies Against the Flu A/Mallard/NL/12/2000 (H7N1) Virus Strain — 39; 45; 42; 46…
Wound Infection Due to Staphylococcus Aureus · MRSA Infection of Postoperative Wound
Primary: Eradication of Staphylococcus Aureus (SA) Carriage at All 4 Body Sites Tested. — 13; 41 Participants
Coronary Artery Disease
Primary: Composite Rate of Cardiac Death and Target Vessel Myocardial Infarction (MI) — 4 Participants
Hypopituitarism
Primary: BOLD Signal Measured by Functional MRI Scan to Functional Connectivity Measured by fMRI
Substance-Related Disorders
Primary: Brain Regions With Increases or Decreases in Amplitude of Low Frequency Fluctuations (ALFF) Associated With Ondansetron Administration — 0.519; 0.562; 0.478; 0.486…
Bradycardia · Sinus Node Dysfunction
Primary: Safety 1 - Percentage of Leads Free From Complication (0 - 3 Months) — 98.4 percentage of leads complication-free
Japanese Premenopausal Healthy Adult Women
Primary: Cmax: Maximum Observed Plasma Concentration for TAK-385 — 23.44; 29.05; 10.94 nanogram per milliliter (ng/mL) — p=0.659
Oral Dystonia · Tardive Dystonia
Primary: Mean Global Dystonia Rating Scale Score as Measured by Blinded Rater — 3.80; 3.57; 3.71 units on a scale
Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: Number of Participants With Good Complete Remission (CR) — 12 Participants
Depressive Disorder, Major
Primary: Change From Randomization to the End of Treatment Phase (Week 6) in the Bech Melancholia Subscale (Bech) (Items 1, 2, 7, 8, 10 and 13) From the Hamilton Rating Scale for…
Tennis Elbow
Primary: Percentage of Patients Reporting at Least 25% Overall Pain Reduction — 88 percentage of patients with less pain
Seborrheic Keratosis
Primary: Proportion of Subjects With Lesion Clearance — 16 Participants
Cystic Fibrosis
Primary: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) — 46; 32; 32; 2 Participants
Plantar Fasciitis, Chronic
Primary: Patient Reported Pain Via the Universal Visual Analog Scale: Pass Criteria = at Least 25% Pain Reduction — 86 Percent of Patients meeting criteria